Skip to main content
SpringerLink
Log in
Book cover

Clinical Cases in Psoriasis pp 95–103Cite as

43-Year-Old with Recurrence of Red, Scaly Rash

  • Chapter
  • First Online:

  • 727 Accesses

Part of the book series: Clinical Cases in Dermatology ((CLIDADE))

Abstract

A 43-year-old male with a 9-year history of well-controlled plaque psoriasis presented with concerns of progressive worsening of his psoriasis symptoms. His psoriasis had been well managed with adalimumab for the past 5 years with less than 1% body surface area affected. However, the patient states that new lesions formed on both upper and lower extremities in the past 4 months. The patient is compliant with his medication regimen and denies any interruptions in treatment. He does not complain of side effects from his medication. The review of systems did not reveal any pertinent positive or negative findings. He denies recent illness, trauma to the skin, or use of new medications. He has no other medical conditions and does not use any other medications. The patient has a maternal family history of psoriasis. The patient is a former smoker and denies the use of alcohol.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310.

    Article  CAS  PubMed  Google Scholar 

  • Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8.

    Article  CAS  PubMed  Google Scholar 

  • Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56.

    Article  CAS  PubMed  Google Scholar 

  • Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241–51.

    Google Scholar 

  • Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol. 2015;135(1):31–8.

    Article  PubMed  Google Scholar 

  • Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB, PHOENIX 1 Investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535–45.

    Article  CAS  PubMed  Google Scholar 

  • Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group, FIXTURE Study Group. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.

    Article  PubMed  Google Scholar 

  • Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K, PHOENIX 2 Investigators. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371–83.

    Article  CAS  PubMed  Google Scholar 

  • Levin EC, Gupta R, Brown G, Malakouti M, Koo J. Biologic fatigue in psoriasis. J Dermatolog Treat. 2014;25(1):78–82.

    Article  CAS  PubMed  Google Scholar 

  • Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–15

    Google Scholar 

  • Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–12.

    Article  CAS  PubMed  Google Scholar 

  • Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84.

    Article  CAS  PubMed  Google Scholar 

  • Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K, PHOENIX 1 Investigators, PHOENIX 2 Investigators, ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–54.

    Article  CAS  PubMed  Google Scholar 

  • Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–74.

    Article  CAS  PubMed  Google Scholar 

  • Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40(1):39–42.

    Article  CAS  PubMed  Google Scholar 

  • Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719–26.

    Google Scholar 

  • van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–72.

    Article  PubMed  Google Scholar 

  • Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56(9):1226–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Warren RB, Smith CH, Yiu ZZ, Ashcroft DM, Barker JN, Burden AD, Lunt M, McElhone K, Ormerod AD, Owen CM, Reynolds NJ, Griffiths CE, BADBIR Study Group. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–40.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Loma Linda University School of Medicine, Loma Linda, CA, USA

    Daniel J. No

  2. University of California, Riverside School of Medicine, Riverside, CA, USA

    Mina Amin

  3. Keck School of Medicine of USC, Los Angeles, CA, USA

    Stacey Pun

  4. Wu Medical Associates, Inc., Los Angeles, CA, USA

    Jashin J. Wu

Authors
  1. Daniel J. No
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mina Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stacey Pun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jashin J. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jashin J. Wu .

Editor information

Editors and Affiliations

  1. Wu Medical Associates, Inc., Los Angeles, California, USA

    Jashin J. Wu

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

No, D.J., Amin, M., Pun, S., Wu, J.J. (2017). 43-Year-Old with Recurrence of Red, Scaly Rash. In: Wu, J. (eds) Clinical Cases in Psoriasis. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-52779-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52779-6_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52778-9

  • Online ISBN: 978-3-319-52779-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation